Jefferies Downgrades Regeneron Pharma (REGN) to Hold, Sees Limited Eylea Upside
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Brean Capital Downgrades Regeneron Pharma (REGN) to Hold
January 17, 2013 8:23 AM ESTBrean Capital downgraded Regeneron Pharma (NASDAQ: REGN) from Buy to Hold saying it would be increasingly difficult for the company to substantially beat consensus as it had quite easily throughout 2012, regardless of a new indication and ex-U.S. approvals.
For an analyst... More
Baird Releases Bullish Note on Regeneron (REGN), Eylea Taking Share
January 15, 2013 2:23 PM ESTToday analysts a Baird put out a very bullish note on Regeneron Pharma (NASDAQ: REGN). In the note, analysts reiterated an Outperform rating and raised thier price target to $205.00 (from $176.00). Analyst also noted strong uptake of Eylea, which continues to take share from Lucentis... More
